KRAS and colorectal carcinoma: A notable phase II trial assessed the application of a 13-mer mutated K-Ras peptide as an adjuvant vaccine in CRC and pancreatic cancer.355 This peptide includes the prevalent G12V mutation and spans 13 amino acids.